• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of direct data communications with Review/Policy Divisions within CDER (Office of Generic Drugs (OGD), Office of New Drug Quality Assessment (ONDQA), Office of Biotechnology Products (OBP), Office of Compliance (OC), Office of New Drugs (OND), CDER/Immediate Office (IO)) and Office of the Commissioner within the month)

Dictionary: The Office of Testing and Research (OTR) is tracking the number of research summaries, findings, and/or results OTR provides to CDER and other Agency customers.


These measures has been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.

Fiscal Year - 2012

Skip graphic and jump to text data

TimeTargetNumber
Oct 2011N/A83
Nov 2011N/A41
Dec 2011N/A55
Jan 2012N/ATBD
Feb 2012N/ATBD
Mar 2012N/ATBD
Apr 2012N/ATBD
May 2012N/ATBD
Jun 2012N/ATBD
Jul 2012N/ATBD
Aug 2012N/ATBD
Sep 2012N/ATBD

FY 2012 YTD: 179

Number of Interim and Final Technical Reports sent to Review/Policy Divisions CDER (OGD, ONDQA, OBP, OC, OND, CDER/IO) and Office of the Commissioner within the month

Dictionary: OTR is tracking the number of technical reports OTR provides to CDER and other Agency customers.

Fiscal Year - 2012

Skip graphic and jump to text data

TimeTargetNumber
Oct 2011N/A18
Nov 2011N/A15
Dec 2011N/A16
Jan 2012N/ATBD
Feb 2012N/ATBD
Mar 2012N/ATBD
Apr 2012N/ATBD
May 2012N/ATBD
Jun 2012N/ATBD
Jul 2012N/ATBD
Aug 2012N/ATBD
Sep 2012N/ATBD

FY 2012 YTD: 49

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.